Top Back to top

HSCT for Congenital Amegakaryocitic thrombopecytopenia (CAMT)

Paediatric Diseases Working Party (PDWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Bone marrow failure
Short title:
CAMT study
Primary objective:
Primary Aim: The aim is to evaluate outcomes of paediatric patients with congenial amegakaryocytic thrombocytopenia.
Key inclusion criteria:
• Age at TX < 18years
• First allogeneic transplant
• Diagnosis: Congenial amegakaryocytic thrombocytopenia
• Year of inclusion: Until 2019 (included
Principal investigator:
Clémence Aldebert
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email: